Tissue transplantation procedures such as periosteum, perichondrium, and osteochondral grafts have yielded positive short-term results for a number of patients, but the long-term clinical results are uncertain, with tissue availability for transplant being a major limitation, especially in large cartilage defects 238910. The autologous chondrocyte implantation (ACI) procedure, first introduced by Brittberg and coworkers 11 in 1994, has been the most widely used surgical procedure (more than 15,000 treatments have been performed). The ACI procedure involves the use of a periosteal flap or a collagen sheet 12, which is fixed to the surrounding cartilage to create a reservoir for injection of a suspension of culture-expanded autologous chondrocytes. A variety of clinical studies have documented the clinical effectiveness of ACI-related procedures for the regeneration of articular cartilage 1314. However, ACI application may be impossible in certain areas of the joint because of anatomic factors, and the fixation of the periosteal flap or collagen sheets covering the chondrocyte suspension may be insecure, especially in degenerative defects that lack an intact cartilage rim. Other potential complications reported have included periosteal hypertrophy, ablation, uneven cell distribution, and loss of cells into the joint cavity 1516, resulting in repetition of surgery in up to 25% to 36% of patients 1217.

Recent technologic improvements have aimed to overcome the intrinsic technical disadvantages of ACI by using cartilage tissue engineering grafts developed with three-dimensional scaffolds or matrices that contain autologous chondrocytes for cartilage regeneration. Biomaterials that have been used include hyaluronan 18 and collagen type I 19, and safety and effectiveness have been demonstrated for cartilage repair 12. Despite these advances, most surgical interventions only result in improvement in clinical symptoms, such as pain relief, and the regeneration of long-lasting hyaline cartilage repair tissue remains a significant challenge 213. Therefore, tissue engineering approaches are being aggressively investigated in an effort to engineer cartilage in vitro to produce grafts that will facilitate regeneration of articular cartilage in vivo. In most cases, chondrocytes or chondroprogenitor cells are harvested by enzymatic digestion or outgrowth culture methods, and then extensively expanded in culture. The cells are then seeded into various biocompatible scaffolds and either further cultured under chondrogenically favorable conditions or implanted immediately 202122.

In a recent study, Ossendorf and coworkers 23 reported favorable repair of focal articular cartilage defects using a modification of ACI based on autologous polymer-based three-dimensional chondrocyte grafts. The polymeric matrix used in this study was BioSeed-C (a polyglycolic/polylactic acid and polydioxane based material), and culture-expanded autologous chondrocytes, suspended in fibrin, are seeded and dispersed within the matrix. BioSeed-C is a proprietary biomaterial marketed by Biotissue Technologies (Freiburg, Germany) as a stable, resorbable, three-dimensional matrix for tissue engineering, particularly for orthopedic and oral applications.

Ossendorf and coworkers 23 evaluated the cell-seeded, two-component, gel-polymer composite in the arthrotomic and arthroscopic treatment of post-traumatic and degenerative cartilage defects in a group of patients suffering from chronic post-traumatic or degenerative cartilage lesions of the knee. Clinical outcome was assessed in 40 patients with a 2-year clinical follow up before implantation and at 3, 6, 12, and 24 months after implantation. Evaluations were based on the modified Cincinnati Knee Rating System, the Lysholm Score, the Knee Injury and Osteoarthritis Outcome Score, and the current health assessment form (36-item Short Form) of the International Knee Documentation Committee, as well as histologic analysis of second-look biopsies. Significant improvement (P < 0.05) in the evaluated scores and histologically observed integration of the graft with the host cartilage tissues were reported. These findings suggest that implantation of autologous chondrocyte-seeded BioSeed-C is an effective treatment option for the regeneration of post-traumatic or osteoarthritic defects of the knee.

The findings reported by Ossendorf and coworkers 23 demonstrate a number of advantages of this second-generation ACI approach over the original procedure. Specifically, by using a stable, three-dimensional matrix, seeded chondrocytes are retained more efficiently at the site of implantation, which should promote integration between the neo-cartilage and the surrounding host articular cartilage tissue. A critical feature of the technology is the use of a gel carrier for the seeded cells to perfuse into the three-dimensional polymer scaffold 2425, a method that essentially anchors the cells within the mechanically stable scaffold while providing an environment that has been shown to enhance the chondrocyte phenotype 26. It should be noted that the report by Ossendorf and coworkers did not provide details on the fabrication protocol of the tissue-engineered cartilage graft. For example, the exact cell density per volume of the construct was not given, and neither were details of the pre-surgery culture expansion of chondrocytes. It would have been helpful to present these details as well as observable characteristics of the engineered tissue grafts, in order to allow evaluation of which parameters are ultimately important for favorable clinical outcomes.

In addition to favorable clinical scores, Ossendorf and coworkers 23 also reported histologic results on second-look biopsies after implantation of the gel-polymer based chondrocyte graft BioSeed-C. The engineered graft showed mostly hyaline cartilage with some fibrocartilage, and presence of viable chondrocytes and absence of calcification, apoptosis, necrosis, and formation of a fibrous repair tissue. However, there was unevenness in the graft in terms of matrix staining, suggesting that the neo-cartilage may not be homogeneous, which could result in compromised mechanical properties. It is noteworthy that the histologic analysis was derived from 18% of the patients who underwent second-look arthroscopy as a result of grinding, catching, pain, or swelling of the knee, a rate comparable to that in other studies reporting rates of revision surgery between 0% and 25% 17. Failure rate with the BioSeed-C procedure was only 2.5% (2/79), which is considerably lower than the 5% to 13% reported in the literature for first-generation ACI 1317. The significantly reduced operating time and the potential for arthroscopic application are additional benefits of the procedure reported here.

Based on the available data, the BioSeed-C procedure represents a potentially significant improvement of the current ACI approach. In particular, the improvement in graft fixation presents the possibility to repair defects that are larger than focal lesions, which currently are the sole indication for ACI. Compared with the use of native matrix materials alone, such as collagen and hyaluronan, the cells are better retained in the mechanically more stable BioSeed-C procedure. Another advantage is that no cover material, such as the periosteum used in the original ACI procedure, is required. It should be noted that in the study conducted by Ossendorf and coworkers 23 no specific selection of osteoarthritic patients was conducted using the more standard International Cartilage Repair Society 27 scoring system, and the classification of osteoarthritis was done primarily based on radiographic observations. A more targeted study in patients with defined osteoarthritis is clearly required to test the applicability of the BioSeed-C procedure for larger sized cartilage repair of osteoarthritic lesions. Further development of the technology described here to repair severe osteoarthritic joints will require the following: a longer term assessment of the biological and clinical outcomes; a better definition of the cellularity requirement of functional cartilage development; and evaluation of potential harmful effects of local acidosis caused by degradation of the biomaterial. Another potential improvement with second-generation ACI is the application of chondroprogenitor cells, for example adult tissue-derived mesenchymal stem cells, instead of articular chondrocytes, in order to minimize additional donor site morbidity caused by cartilage harvesting. To accomplish this, the scaffold used must also serve the purpose of delivering chondro-inductive factors and signals.